Mers CoV Virus Gene Replikins Found Conserved and Shared in Current Strains Back to 2012 - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Mers CoV Virus Gene Replikins Found Conserved and Shared in Current Strains Back to 2012 New Analysis Provides Basis for a Synthetic Mers CoV Blocker-Vaccine Candidate Now Available for Testing


Mers CoV Virus Gene Replikins Found Conserved and Shared in Current Strains Back to 2012

New Analysis Provides Basis for a Synthetic Mers CoV Blocker-Vaccine Candidate Now Available for Testing

PR Newswire

LONDON, Aug. 26, 2014 /PRNewswire/ -- An analysis by Replikins, Ltd. of Pubmed data of the gene structures of all Mers CoV virus strains has revealed extensive conservation and sharing of specific Replikin structures back to 2012.  This conservation and sharing of specific Replikin gene structures has permitted the formulation of a Synthetic Mers CoV Blocker-Vaccine candidate, as it did for the H5N1 influenza vaccine and the Taura Syndrome Shrimp vaccine, both of which have been found to be effective (1,2).

This Mers CoV vaccine candidate is synthesized in five days and is available freeze-dried to governments and other institutions for testing and use according to the country's regulatory bodies.

The Replikin Count of Mers CoV gene has continued to increase rather than to decrease as its relative SARS did in 2003 to signal cessation of that outbreak.

For further information: < Email > 646-320-5910

References:

1. Jackwood et al. Efficacy of a Replikin Peptide Vaccine Against Low-Pathogenicity Avian Influenza H5 Virus. Avian Diseases 53:613-617, 2009.

2. Bogoch S and Bogoch ES. Prediction of specific virus outbreaks made from the increased concentration of a new class of virus genomic peptides, replikins. Nature Precedings doi:10.1038/npre.2011.6279.1


SOURCE Replikins, Ltd.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here